248 related articles for article (PubMed ID: 19001435)
1. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Yang F; Jove V; Xin H; Hedvat M; Van Meter TE; Yu H
Mol Cancer Res; 2010 Jan; 8(1):35-45. PubMed ID: 20053726
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R
Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Chai H; Luo AZ; Weerasinghe P; Brown RE
Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z
Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427
[TBL] [Abstract][Full Text] [Related]
13. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
14. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib exerts anti-glioma activity in vitro and in vivo.
Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Delgado JS; Mustafi R; Yee J; Cerda S; Chumsangsri A; Dougherty U; Lichtenstein L; Fichera A; Bissonnette M
Dig Dis Sci; 2008 Dec; 53(12):3055-64. PubMed ID: 18512153
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
